Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Overview

cited authors

Niesvizky, Ruben; Flinn, Ian; Rifkin, Robert M.; Essell, James; Gaffar, Yousuf; Warr, Thomas; Neuwirth, Rachel; Ba-Mancini, Abbie; Zhu, Yanyan; Niculescu, Liviu; Reeves, James

authors

Gaffar, Yousuf, MD

Publication Date

November 15, 2013

webpage

Web of Science

published in

BLOOD Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.